Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2014 2
2015 3
2016 3
2017 5
2018 5
2019 11
2020 10
2021 4
2022 10
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, Bretagne MC, Salem JE, Declèves X, Vidal M, Kramkimel N, Guegan S, Aractingi S, Huillard O, Alexandre J, Wislez M, Goldwasser F, Blanchet B. Puszkiel A, et al. Among authors: arrondeau j. Br J Cancer. 2024 Mar 26. doi: 10.1038/s41416-024-02659-x. Online ahead of print. Br J Cancer. 2024. PMID: 38532102
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet JF, Rufat P, Bonnefont-Rousselot D, Batista R, Terris B, Bellanger A, Thabut D, Vozy A, Spano JP, Coriat R, Goldwasser F, Aractingi S, Sogni P, Pol S, Mallet V; CERTIM Research Group; DEMOSTHENES Research Group. Parlati L, et al. JHEP Rep. 2023 Aug 12;5(12):100880. doi: 10.1016/j.jhepr.2023.100880. eCollection 2023 Dec. JHEP Rep. 2023. PMID: 38074948 Free PMC article.
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
Balakirouchenane D, Seban R, Groussin L, Puszkiel A, Cottereau AS, Clerc J, Vidal M, Goldwasser F, Arrondeau J, Blanchet B, Huillard O. Balakirouchenane D, et al. Among authors: arrondeau j. Thyroid. 2023 Nov;33(11):1327-1338. doi: 10.1089/thy.2023.0228. Epub 2023 Oct 12. Thyroid. 2023. PMID: 37725566
Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors.
Ashton E, Arrondeau J, Jouinot A, Boudou-Rouquette P, Hirsch L, Huillard O, Ulmann G, Lupo-Mansuet A, Damotte D, Wislez M, Alifano M, Alexandre J, Goldwasser F. Ashton E, et al. Among authors: arrondeau j. Clin Nutr. 2023 Jun;42(6):944-953. doi: 10.1016/j.clnu.2023.03.023. Epub 2023 Apr 14. Clin Nutr. 2023. PMID: 37099986
Predictive factors associated with pemetrexed acute toxicity.
Bonnet M, Jouinot A, Boudou-Rouquette P, Seif V, Villeminey C, Arrondeau J, Vidal M, Batista R, Wislez M, Blanchet B, Goldwasser F, Thomas-Schoemann A. Bonnet M, et al. Among authors: arrondeau j. Eur J Clin Pharmacol. 2023 May;79(5):635-641. doi: 10.1007/s00228-023-03478-4. Epub 2023 Mar 23. Eur J Clin Pharmacol. 2023. PMID: 36951965
Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
Ginguay A, Kramkimel N, Lecolant S, Goldwasser F, Battistella M, Arrondeau J. Ginguay A, et al. Among authors: arrondeau j. Case Rep Oncol. 2022 Dec 21;15(3):1114-1119. doi: 10.1159/000525524. eCollection 2022 Sep-Dec. Case Rep Oncol. 2022. PMID: 36655184 Free PMC article.
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
Rodier T, Puszkiel A, Cardoso E, Balakirouchenane D, Narjoz C, Arrondeau J, Fallet V, Khoudour N, Guidi M, Vidal M, Declèves X, Csajka C, Alexandre J, Cadranel J, Fabre E, Wislez M, Goldwasser F, Blanchet B. Rodier T, et al. Among authors: arrondeau j. Pharmaceutics. 2022 Sep 1;14(9):1844. doi: 10.3390/pharmaceutics14091844. Pharmaceutics. 2022. PMID: 36145591 Free PMC article.
Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab.
Noel J, Jouinot A, Alexandre J, Ulmann G, Bretagne M, Castel-Ajgal Z, De Percin S, Vaquin-Villeminey C, Revel MP, Peyromaure M, Boudou-Rouquette P, Arrondeau J, Gataa I, Durand JP, Goldwasser F, Huillard O. Noel J, et al. Among authors: arrondeau j. Cancers (Basel). 2022 Jun 30;14(13):3214. doi: 10.3390/cancers14133214. Cancers (Basel). 2022. PMID: 35804986 Free PMC article.
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
Velut Y, Decroix E, Blons H, Alifano M, Leroy K, Petitprez F, Boni A, Garinet S, Biton J, Cremer I, Wislez M, Boudou-Rouquette P, Arrondeau J, Goldwasser F, Fournel L, Damotte D, Mansuet-Lupo A. Velut Y, et al. Among authors: arrondeau j. Lung Cancer. 2022 Jul;169:13-21. doi: 10.1016/j.lungcan.2022.05.001. Epub 2022 May 5. Lung Cancer. 2022. PMID: 35597058
Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.
Castel-Ajgal Z, Goulvestre C, Zaibet S, Arrondeau J, Bretagne M, Peyromaure M, Batteux F, Alexandre J, Goldwasser F, Huillard O. Castel-Ajgal Z, et al. Among authors: arrondeau j. Clin Genitourin Cancer. 2022 Oct;20(5):e362-e368. doi: 10.1016/j.clgc.2022.04.002. Epub 2022 Apr 21. Clin Genitourin Cancer. 2022. PMID: 35577731
54 results